English » Μolecular Analyses » Circulating tumor cells (CTCs) » Quantification of Androgen Receptor (AR) splice variants in CTCs

Quantification of Androgen Receptor (AR) splice variants in CTCs

Detection and quantification of Androgen Receptor (AR) splice variants of CTCs

in peripheral blood of prostate cancer patients


  • Splice variants: AR-V7, AR-567es, AR wild type, AR total
  • Methodology: multiplex RT-qPCR 
  • Instrumentation: LightCycler 2.0 (IVD, Roche Diagnostics)
  • Analytical characteristics: exceptional analytical sensitivity and specificity
  • Requested sample: 20mL peripheral blood (EDTA) - pre-, during or post-therapy
  • Cost: please contact Dr E.Lianidou (lianidou@chem.uoa.gr)


  • Publications: 

Strati A, Zavridou M, Bournakis E, Mastoraki S, Lianidou E. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. Analyst 2019 Nov;144:6671-6680

 

  • Clinical importance:
  1. Antonarakis ES, et al, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014 Sep 11;371(11):1028-38.
  2. Nadal R, et al, Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. Prostate. 2015 Dec 22.
  3. Maughan BL, Antonarakis ES. Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. Curr Treat Options Oncol. 2015 Dec;16(12):57 
  4. Schweizer MT, Antonarakis ES. Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med. 2015 Nov 4;7(312):312fs45.
  5. Antonarakis ES, Luo J. Prostate cancer: AR splice variant dimerization-clinical implications. Nat Rev Urol. 2015 Aug;12(8):431-3.
  6. Antonarakis ES, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2015 Aug;1(5):582-91.
  7. Nakazawa M, et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015 Sep;26(9):1859-65
  8. Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015;16(10):1521-37.